Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements...
Hence then, the article about ucb presents positive results from gemz phase 3 study at aes showing fenfluramine significantly reduces countable motor seizure frequency in cdkl5 deficiency disorder was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder )
Also on site :
- Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery
- J.J. Abrams on ‘The End of Oak Street’ Theories and Daughter Gracie’s Acting Debut: “I Know How Hard She’s Working”
- T.J. Maxx's Set of Perfect-for-Fall Mugs Is Just $15, So You'll Want to Grab It Before It's Gone for Good